Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Klinge Pharma GmbH

Division of Astellas Pharma Inc.
www.klinge.de/

Latest From Klinge Pharma GmbH

CAT Fight with Abbott: The Calculus of Royalty Offsets and Partnering Reputation

The fight between Abbott Laboratories and Cambridge Antibody Technology over two partly overlapping royalty-giveback clauses in their contract on Humira has implications far beyond the money--which itself is not inconsiderable. Abbott could theoretically save itself some $60 million in royalty fees, but it could also win itself a name for playing hardball with its partners, even in the event of a major drug development success.
BioPharmaceutical Strategy

Biotech's Euro-Marketing Gambit

Europe presents a big opportunity--but also significant challenges--to niche players seeking to expand. Some firms--such as US group Cephalon--have bought big in Europe, others like Shire and Celltech have made do with smaller acquisitions onto which they hope to build their own tailored infrastructure. No single approach is the same, and none has yet proven a clear winner. But all depend on finding the right products.
BioPharmaceutical Strategy

Alzheimer's Disease: A disease in search of a drug

We're still in the iron lung age of Alzheimer's treatment. When the new Jonas Salk comes along, ideas will change dramatically.
BioPharmaceutical Medical Device

Merck KGAA: Reinventing the Mid-Sized Public Company

Merck's goal is to build a leading position in specialty OTCs as well as a worldwide generics business, both goals designed to offset the risks of its R&D program. Its new business allows it to use its size as an advantage against smaller, specialized players while avoiding direct competition with the larger multinationals.
BioPharmaceutical Consumer
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register